 Treatment NIDDM insulin agonists substitutes Non-insulin-dependent diabetes NIDDM common disorder adults western populations United patients diabetes insulin NIDDM Insulin therapy time NIDDM Insulin therapy abnormalities NIDDM beta-cell function hepatic glucose production peripheral glucose disposal lipid abnormalities Insulin sulfonylurea agents comparable effects mild forms NIDDM severe forms insulin superior Combination insulin-sulfonylurea treatment response long-term well-controlled trials Short-term insulin treatment response sulfonylureas Other promising treatments human proinsulin nasal insulin somatostatin advantage conventional insulin therapy Insulin hypoglycemia peripheral hyperinsulinemia hazards hyperinsulinemia gain hypoglycemia questions atherogenic effects effect glycemic control macro- microvascular complications blood glucose levels mM progression retinopathy neuropathy nephropathy severity ischemic stroke Dosage intermediate- long-acting insulin basal glycemia regular insulin meals postprandial glycemia Effective therapy patient cooperative willing self-monitor blood glucose Insulin treatment intermittency risk immune complications resistance allergy Overall patients NIDDM insulin therapy